SFA Therapeutics, Inc. news

SFA Therapeutics, Inc., a clinical-stage biotechnology company, is pleased to announced the start of our first clinical trial for the treatment of “the appearance of the structure of skin with plaques due to psoriasis.” SFA plans to expand the evaluation of one of its six microbiome-derived drugs, SFA002, in this new trial.

This 30-subject open-label clinical trial in patients with mild-to-moderate psoriasis will enro

TUE, OCT 13 2020 9:00 AM—FRI, OCT 30 2020 4:00 PM

SFA Therapeutics has been selected to present at the The 24th annual Angel Venture Fair It is virtual this year .

There were over 150 applicants and our 85 judges narrowed down to this amazing cross section of companies.  What is unique about this

PRLog - SFA Therapeutics, Inc. announced today that FDA has granted an official Orphan Drug Designation (ODD) to SFA001, the company`s novel human-microbiome-based treatment for human hepatocellular carcinoma (HCC).

"By granting an Orphan Drug Designation to SFA001, FDA has given a special status to treatment of the most prevalent form of liver cancer. This ODD designation will provide SFA Therapeutics with significant drug development and tax advantages as well as an expanded period

The orphan drug designation will provide SFA Therapeutics with significant drug development and tax advantages as well as an expanded period of market exclusivity.